SHARE - Symbicort and Health Economics in a Real Life Evaluation

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate; Terbutaline

Criteria

Inclusion Criteria:

• Signed informed consent,

• asthma,

• previously treated with glucocorticosteroids and B2-agonist

Exclusion Criteria:

• History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation